Funding agencies: This study was supported by NIH/NINDS grant P50 NS072187, Mayo Clinic Florida Research Committee, and the gift from Carl Edward Bolch, Jr., and Susan Bass Bolch.
In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers
Article first published online: 5 MAY 2014
© 2014 International Parkinson and Movement Disorder Society
Volume 29, Issue 9, pages 1197–1201, August 2014
How to Cite
Felicio, A. C., Dinelle, K., Agarwal, P. A., McKenzie, J., Heffernan, N., Road, J. D., Appel-Cresswell, S., Wszolek, Z. K., Farrer, M. J., Schulzer, M., Sossi, V. and Stoessl, A. J. (2014), In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers. Mov. Disord., 29: 1197–1201. doi: 10.1002/mds.25893
Relevant conflicts of interest/financial disclosures: Nothing to report.
Full financial disclosures and author roles may be found in the online version of this article.
- Issue published online: 18 AUG 2014
- Article first published online: 5 MAY 2014
- Manuscript Accepted: 25 MAR 2014
- Manuscript Revised: 10 MAR 2014
- Manuscript Received: 1 NOV 2013
This article has been cited by:
- 1Whole exome sequencing and the clinician: we need clinical skills and functional validation in variant filtering, Journal of Neurology, 2015, 262, 7, 1673, , , , , , , ,